This can lead to: Intense, persistent nausea Projective or repetitive vomiting Severe abdominal cramping and bloating Significant dehydration due to the inability to keep fluids down Risk of Hypoglycemia While GLP-1 medications are generally known for having a low risk of causing low blood sugar (hypoglycemia) when used alone, taking excessive amounts changes the equation
How it works: Semaglutide mimics the natural GLP-1 hormone your body produces after eating, helping regulate blood sugar, slow digestion, and reduce appetite
Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
It is also useful in improving blood flow by boosting the production of nitric oxide in the body